Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
NFL
U.S.
2024 Election
Local
World
Science
Technology
AI
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
FDA approves First RSV vaccine for adults under 60
FDA Expands Approval of RSV Vaccine Abrysvo to Include All At-Risk Adults
The FDA expanded the approval of the bivalent RSV prefusion F (RSVpreF) vaccine (Abrysvo) to include the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in high-risk adults ages 18 to 59 years, Pfizer announced on Tuesday.
FDA approves Pfizer's RSV shot Abrysvo for all at-risk adults
While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to determine how much advantage will be gained from the nod as the Centers for Disease Control (CDC) will have to sign off on Abvrysvo's use in the wider age group.
Pfizer’s RSV vaccine cleared by FDA for use in some younger adults
Approval of Pfizer's Abrysvo in certain adults aged 18 to 59 years old will substantially expand the number of people eligible for vaccination with the shot.
RSV Vaccine Abrysvo Approved for Adults Aged 18 to 59 at Increased Risk
The Food and Drug Administration (FDA) has approved Abrysvo ® (respiratory syncytial virus [RSV] vaccine) for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 to 59 years of who are at increased risk for LRTD caused by RSV.
Pfizer gets a leg up in RSV as FDA clears jab for all adults
A new FDA approval has given Pfizer a broader label for its respiratory syncytial virus (RSV) vaccine Abrysvo than rival shots from GSK and Moderna, but it may not make much of a difference in the battle for market share.
US FDA approves Pfizer's RSV vaccine for adults at increased risk of the disease
The U.S. Food and Drug Administration on Tuesday approved Pfizer's RSV vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at increased risk of the disease.
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at risk from RSV disease,” the company’s chief scientific officer, Tony Wood, Ph.D., said in a release. “They also provide valuable insights into the potential impact of a second dose for certain populations.”
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
Pfizer's RSV vaccine Abrysvo receives FDA approval for adults 18-59 at high risk, with extended use for pregnant individuals to safeguard infants from birth.
FDA expands Pfizer’s RSV vaccine label to include all high-risk adults
Abrysvo is now approved to prevent lower respiratory tract disease caused by RSV in high-risk adults over 18 years of age.
Pfizer Receives FDA Approval for RSV Vaccine
Abrysvo can prevent lower respiratory tract disease caused by RSV for people between the ages of 18 and 59 who are at increased risk. It is the first RSV vaccine indicated for adults younger than 50,
The American Journal of Managed Care
4d
FDA Approves Abrysvo RSV Vaccine for Adults at Increased Risk
Abrysvo is the first and only respiratory syncytial virus (RSV) vaccine indicated for adults younger than 50 years.
5d
Pfizer Receives Expanded FDA Approval for RSV Vaccine
Abrysvo is the first vaccine for the respiratory syncytial virus that is indicated for adults younger than 50, the drugmaker ...
BioPharma Dive
2d
Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback